China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its second-generation AcoStream, a product designed to remove blood clots in the peripheral vascular system.
Advancement in Blood Clot Removal Technology
The first-generation version of AcoStream was approved for marketing in China in November 2021. The approval of the second-generation product signifies a continued advancement in the field of vascular health, offering improved solutions for the treatment of blood clot-related conditions in the peripheral vascular system.-Fineline Info & Tech
